

# Case Report

## A Child with Constipation and Swollen Abdomen

**Urgent message:** Malignancies in children are often discovered only inadvertently, in conjunction with seemingly less dire presentations. Awareness of relevant signs and symptoms by the urgent care clinician can be invaluable in identifying tumors that might otherwise escape notice until they are at an advanced stage.

Muhammad Waseem, MD

### Introduction

The identification of a palpable abdominal mass in an urgent care center or emergency department is quite concerning, as it represents a serious underlying disorder. Any abdominal mass in a child is usually considered malignant until proven otherwise. Abdominal tumors are uncommon in children and can present with pain, vomiting, or abdominal mass.

Here, we report on a child who presented with history of constipation and an abdominal mass that was identified on physical examination and subsequently diagnosed as neuroblastoma.

### Case Study

A 15-month-old female presented with a two-day history of constipation. There was no vomiting, fever, or abdominal pain. She previously had been in good



© iStockphoto/Sean Locke

health and had seen her pediatrician regularly. Her parent also noted her to have a swollen abdomen, which they attributed to “constipation.” She had been evaluated for this by her pediatrician and was taking stool softeners.


### Findings

Physical examination revealed a well-developed, comfortable child with:

- temperature 99°F (36.9°C)
- pulse 108 beats per min
- BP 99/62 mmHg
- respiration 20 per minute.


The patient’s abdomen was mildly distended, with fullness on the left side and flank. A somewhat firm, nontender, nonmobile mass with rounded margins was palpable in the left lower quadrant and left lumbar regions. No guarding, rigidity, or tenderness was noted. Bowel sounds were audible. Rectal examination

Figure 1.



Renal ultrasound showing a retroperitoneal mass in the left flank.

Figure 2.



A contrast computed tomography (CT) scan of abdomen showing a left retroperitoneal mass between the left kidney and upper lumbar spine, with some displacement of the left kidney.

revealed no tenderness or masses; rectal vault was empty. The remainder of the physical examination was unremarkable.

Other findings included:

- white blood cell count  $9.3 \times 10^3/\text{mcL}$  ( $11.1 \times 10^9/\text{L}$ )
- 29.1% neutrophils

- 56.4% lymphocytes
- 12.7% monocytes
- 1.2% eosinophils
- 0.6% basophils
- hemoglobin 11.3 g/dL
- platelet count was  $733 \times 10^3/\text{mcL}$  ( $733 \times 10^9/\text{L}$ )
- serum electrolytes were normal
- aspartate aminotransferase 43 U/L
- alanine aminotransferase 16 U/L
- albumin 3.8 g/dL
- bilirubin 0.3 mg/dL
- alkaline phosphatase 188 U/L
- lactic dehydrogenase 317 U/L (105-215).
- Urinalysis yielded normal findings.

The initial renal ultrasound showed a retroperitoneal mass in the left flank without hydronephrosis or intrinsic renal mass (**Figure 1**). Subsequently, a contrast computed tomography (CT) scan of the abdomen revealed a left retroperitoneal mass between the left kidney and upper lumbar spine, with some displacement of the left kidney (**Figure 2**). The urinary catecholamine metabolites, homovanillic acid (HVA), and vanillylmandelic acid (VMA) were also elevated.

The patient was referred to an affiliated tertiary care center for sub-specialty care.

### Discussion

The child with an abdominal mass presents a unique challenge. A palpable mass in the abdomen of a child is a serious finding, with a fairly extensive differential diagnosis.

Abdominal masses may occur at any age, and may have a wide variety of clinical presentations. It is the urgent care clinician's role to differentiate between benign conditions such as constipation and more serious causes of abdominal mass (**Table 1**).

When an abdominal mass is discovered on physical examination, the immediate goal is to determine its nature and extent. A tentative diagnosis can often be made from the presenting symptoms, age of the child, and the site of mass. Physical examination should focus on the location, size, and mobility of the mass, as well as other

## Vigamox<sup>®</sup>

(moxifloxacin hydrochloride ophthalmic solution) 0.5% as base

**DESCRIPTION:** VIGAMOX<sup>®</sup> (moxifloxacin HCl ophthalmic solution) 0.5% is a sterile ophthalmic solution. It is an 8-methoxy fluoroquinolone anti-infective for topical ophthalmic use.

### CLINICAL PHARMACOLOGY:

#### Microbiology:

The following *in vitro* data are also available, but their clinical significance in ophthalmic infections is unknown. The safety and effectiveness of VIGAMOX<sup>®</sup> solution in treating ophthalmological infections due to these microorganisms have not been established in adequate and well-controlled trials. The following organisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between the *in vitro* systemic breakpoint and ophthalmological efficacy has not been established. The list of organisms is provided as guidance only in assessing the potential treatment of conjunctival infections. Moxifloxacin exhibits *in vitro* minimal inhibitory concentrations (MICs) of 2 µg/ml or less (systemic susceptible breakpoint) against most (≥ 90%) strains of the following ocular pathogens.

#### Aerobic Gram-positive microorganisms:

*Listeria monocytogenes*  
*Staphylococcus saprophyticus*  
*Streptococcus agalactiae*  
*Streptococcus mitis*  
*Streptococcus pyogenes*  
*Streptococcus Group C, G and F*

#### Aerobic Gram-negative microorganisms:

*Acinetobacter baumannii*  
*Acinetobacter calcoaceticus*  
*Citrobacter freundii*  
*Citrobacter koseri*  
*Enterobacter aerogenes*  
*Enterobacter cloacae*  
*Escherichia coli*  
*Klebsiella oxytoca*  
*Klebsiella pneumoniae*  
*Moraxella catarrhalis*  
*Morganella morganii*  
*Neisseria gonorrhoeae*  
*Proteus mirabilis*  
*Proteus vulgaris*  
*Pseudomonas stutzeri*

#### Anaerobic microorganisms:

*Clostridium perfringens*  
*Fusobacterium species*  
*Prevotella species*  
*Propionibacterium acnes*

#### Other microorganisms:

*Chlamydia pneumoniae*  
*Legionella pneumophila*  
*Mycobacterium avium*  
*Mycobacterium marinum*  
*Mycoplasma pneumoniae*

#### Clinical Studies:

In two randomized, double-masked, multicenter, controlled clinical trials in which patients were dosed 3 times a day for 4 days, VIGAMOX<sup>®</sup> solution produced clinical cures on day 5-6 in 66% to 69% of patients treated for bacterial conjunctivitis. Microbiological success rates for the eradication of the baseline pathogens ranged from 84% to 94%. Please note that microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.

**INDICATIONS AND USAGE:** VIGAMOX<sup>®</sup> solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:

#### Aerobic Gram-positive microorganisms:

*Corynebacterium species\**  
*Micrococcus luteus\**  
*Staphylococcus aureus*  
*Staphylococcus epidermidis*  
*Staphylococcus haemolyticus*  
*Staphylococcus hominis*  
*Staphylococcus warneri\**  
*Streptococcus pneumoniae*  
*Streptococcus viridans group*

#### Aerobic Gram-negative microorganisms:

*Acinetobacter lwoffii*  
*Haemophilus influenzae*  
*Haemophilus parainfluenzae\**

#### Other microorganisms:

*Chlamydia trachomatis*

\*Efficacy for this organism was studied in fewer than 10 infections.

**CONTRAINDICATIONS:** VIGAMOX<sup>®</sup> solution is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication.

#### WARNINGS:

NOT FOR INJECTION.

VIGAMOX<sup>®</sup> solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.

In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. If an allergic reaction to moxifloxacin occurs, discontinue use of the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.

#### PRECAUTIONS:

**General:** As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy,

and, where appropriate, fluorescein staining. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.

**Information for Patients:** Avoid contaminating the applicator tip with material from the eye, fingers or other source.

Systemically administered quinolones including moxifloxacin have been associated with hypersensitivity reactions, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction.

**Drug Interactions:** Drug-drug interaction studies have not been conducted with VIGAMOX<sup>®</sup> solution. *In vitro* studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed. However, in an accelerated study with initiators and promoters, moxifloxacin was not carcinogenic in rats following up to 38 weeks of oral dosing at 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose for a 50 kg person, on a mg/kg basis).

Moxifloxacin was not mutagenic in four bacterial strains used in the Ames *Salmonella* reversion assay. As with other quinolones, the positive response observed with moxifloxacin in strain TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when v79 cells were used. Moxifloxacin was clastogenic in the v79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity *in vivo* in a micronucleus test or a dominant lethal test in mice.

Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 21,700 times the highest recommended total daily human ophthalmic dose. At 500 mg/kg/day orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.

#### Pregnancy: Teratogenic Effects.

**Pregnancy Category C:** Moxifloxacin was not teratogenic when administered to pregnant rats during organogenesis at oral doses as high as 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose); however, decreased fetal body weights and slightly delayed fetal skeletal development were observed. There was no evidence of teratogenicity when pregnant Cynomolgus monkeys were given oral doses as high as 100 mg/kg/day (approximately 4,300 times the highest recommended total daily human ophthalmic dose). An increased incidence of smaller fetuses was observed at 100 mg/kg/day.

Since there are no adequate and well-controlled studies in pregnant women, VIGAMOX<sup>®</sup> solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Nursing Mothers:** Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when VIGAMOX<sup>®</sup> solution is administered to a nursing mother.

**Pediatric Use:** The safety and effectiveness of VIGAMOX<sup>®</sup> solution in infants below 1 year of age have not been established.

There is no evidence that the ophthalmic administration of VIGAMOX<sup>®</sup> solution has any effect on weight bearing joints, even though oral administration of some quinolones has been shown to cause arthropathy in immature animals.

**Geriatric Use:** No overall differences in safety and effectiveness have been observed between elderly and younger patients.

#### ADVERSE REACTIONS:

The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1-6% of patients. Nonocular adverse events reported at a rate of 1-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.

Rx only

Manufactured by Alcon Laboratories, Inc.  
Fort Worth, Texas 76134 USA

Licensed to Alcon, Inc. by Bayer HealthCare AG.  
U.S. PAT. NO. 4,990,517; 5,607,942; 6,716,830  
©2003, 2004, 2006, Alcon, Inc.

#### References:

- Lichtenstein SJ, Dorfman M, Kennedy R, Stroman D. Controlling contagious bacterial conjunctivitis. *J Pediatr Ophthalmol Strabismus*. 2006;43:19-26.
- Data on file. Alcon Laboratories, Inc.

## CASE REPORT

### Table 1. Common Causes of Abdominal Mass in Children

- Wilms' tumor
- Neuroblastoma
- Lymphoma
- Polycystic or dysplastic kidney
- Hydronephrosis
- Hepatoblastoma
- Teratoma
- Ovarian cyst
- Constipation/fecal mass

Source: Ruddy RM. emergency presentations of cancer in childhood. *Clin Ped Emerg Med*. 2005;6(3):184-191.

abnormalities on examination. The examination should also include measurement of serial blood pressures and a complete neurological assessment.

The presence of an abdominal mass may indicate the existence of colonic stools or tumors. In constipation, a mass can be palpated, which is usually associated with fecal impaction on rectal examination. Wilms' tumor and neuroblastoma (NB) are the two common intra-abdominal masses in children. These are more prevalent in children younger than 4 years.

NB is the most common extracranial tumor in children,<sup>1</sup> accounting for 10% of pediatric malignancies. After tumors of the central nervous system, it is the most common solid tumor in children.<sup>2</sup> It is also the most common malignant tumor of infancy, with 50% of cases occurring in children younger than 2 years of age and 75% diagnosed by the fourth year of life.

The median age at diagnosis is 2 years, but the tumor may present in the neonate or even in adolescents and adults.<sup>3</sup> NB occurs most commonly in the abdomen (65%), either in the sympathetic chain or more commonly in the adrenal gland.<sup>4,5</sup> After the abdomen, the thorax is the second most common location of NB (15%) followed by the neck (1% to 5%) and the pelvis (2% to 3%).<sup>6</sup>

### Clinical Presentation

NB may have diverse clinical features because of its variable sites of origin, propensity to metastasize, and secretion of hormones. Clinical features at presentation depend on the size and location of the primary tumor, and on whether the tumor has

metastasized. Between 50% and 70% of patients with NB may have metastasis at the time of their presentation.<sup>7</sup> Large masses may cause respiratory distress. The common sites for distant metastasis include the bone marrow, liver, and skin.<sup>8</sup>

The signs and symptoms of this tumor are dependent on the location of the primary tumor, which may occur anywhere along the peripheral sympathetic nervous system, and the sites of metastatic disease. Typically the initial symptoms are nonspecific (general malaise, weight loss, unexplained fever), as in most patients the tumor is either retroperitoneal or in posterior mediastinum.<sup>9</sup>

#### Common symptoms

The common symptoms are:

- abdominal pain or discomfort
- sensation of fullness
- fever
- weight loss.

Although most children present with abdominal pain or a palpable mass, many present with manifestations of their metastatic disease, including bone or joint pain and periorbital ecchymosis.

#### Diagnostic Evaluation

An abdominal mass in a child must be considered malignant until proven otherwise. As such, any studies described here but not feasible for the urgent care setting should be facilitated via referral. They are included here for the sake of presenting as complete a picture of the diagnostic process as possible.

When an abdominal mass is detected in a child, imaging studies should be performed. Ultrasound is helpful in the initial evaluation of a child with an abdominal mass, as it is useful in determining the origin of the mass. It will also help determine whether the mass is cystic or solid.

Abdominal CT scan is a commonly used imaging modality for the assessment of a child with abdominal mass. It offers several advantages in the differential diagnosis of a possible Wilms' tumor, such as confirmation of the intrarenal origin of the tumor, detection of multiple masses, determination of the extent of tumor, and evaluation of the opposite kidney.

Initial laboratory studies should include a complete blood count to identify anemia or thrombocytopenia suggestive of bone marrow invasion. NB produces catecholamine metabolites, which are used as tumor markers; therefore, a search for specific tumor markers se-

creted by the suspected tumor should also be made.

Elevation of urinary catecholamine metabolites, homovanillic acid (HVA), and vanillylmandelic acid (VMA) is used as a diagnostic screen,<sup>10,11</sup> as this is present in 75% to 90% of patients with NB.<sup>12</sup>

#### Differential Diagnosis

Most abdominal masses in infants are due to problems of the urinary tract. Hydronephrosis and multicystic kidney are common causes of flank masses at this age.<sup>13</sup> If a mass appears to be in the flank in an older infant or child, Wilms' tumor and NB should be considered.

Additional features suggestive of Wilm's tumor include fever, abdominal pain, or hematuria.

Hepatoblastoma is the most common primary hepatic tumor in young children. A high serum alpha-fetoprotein is often noted.

Lymphoproliferative conditions can also present with an abdominal mass. A suprapubic mass may be due to a distended bladder, which in turn may be secondary to urinary tract obstruction.

#### Conclusion

The presence of an abdominal mass in children includes a wide spectrum of diseases. This case emphasizes the value of performing a careful and thorough physical examination upon presentation. The presence of an abdominal mass should generate the suspicion for the possibility of tumor. ■

#### References

1. Chandler JC, Gauderer MW. The neonate with an abdominal mass. *Pediatr Clin North Am.* 2004;51:979-997.
2. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. *Principles and Practice of Pediatric Oncology.* 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins;2002: 895-937.
3. McLean TW, Iskandar SS, Shimada H, et al. Neuroblastoma in an adult. *Urology.* 2004;64:1232.
4. Bousvaros A, Kirks DR, Grossman H. Imaging of neuroblastoma: A overview. *Pediatr Radiol.*1986;16:89-106.
5. Brouwers FM, Eisenhofer G, Lenders JW, et al. Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. *Endocrinol Metab Clin North Am.* 2006;35:699-724.
6. Hiorns MP, Owens CM. Radiology of neuroblastoma in children. *Eur Radiol.* 2001;11:2071-2081.
7. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. *J Pediatr Hematol Oncol.* 1999;21:181-189.
8. Castleberry RP. Biology and treatment of neuroblastoma. *Pediatr Clin North Am.* 1997;44:919-937.
9. Kim S, Chung DH. Pediatric solid malignancies: Neuroblastoma and Wilms' tumor. *Surg Clin North Am.* 2006;86:469-487.
10. Laug WE, Siegel SE, Shaw KN, et al. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. *Pediatrics.* 1978;62:77-83.
11. Shaw PH, Dickman PS. Neuroblastoma mimicking rhabdoid tumor of the kidney. *J Pediatr Hematol Oncol.* 2003;25:572-574.
12. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. *Oncologist.* 2003;8:278-292.
13. Chandler JC, Gauderer MW. The neonate with an abdominal mass. *Pediatr Clin North Am.* 2004;51:979-997.